Cargando…

A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma

BACKGROUND: Treatments for patients with early‐stage hepatocellular carcinoma (HCC) include liver transplantation (LT), liver resection (LR), radiofrequency ablation (RFA), and microwave ablation (MWA), are critical for their long-term survival. However, a computational model predicting treatment-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shu-Wen, Zhang, Ning-Ning, Zhu, Wen-Wen, Liu, Tian, Lv, Jia-Yu, Jiang, Wen-Tao, Zhang, Ya-Min, Song, Tian-Qiang, Zhang, Li, Xie, Yan, Zhou, Yong-He, Lu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352894/
https://www.ncbi.nlm.nih.gov/pubmed/35936698
http://dx.doi.org/10.3389/fonc.2022.946531
_version_ 1784762749364994048
author Zhang, Shu-Wen
Zhang, Ning-Ning
Zhu, Wen-Wen
Liu, Tian
Lv, Jia-Yu
Jiang, Wen-Tao
Zhang, Ya-Min
Song, Tian-Qiang
Zhang, Li
Xie, Yan
Zhou, Yong-He
Lu, Wei
author_facet Zhang, Shu-Wen
Zhang, Ning-Ning
Zhu, Wen-Wen
Liu, Tian
Lv, Jia-Yu
Jiang, Wen-Tao
Zhang, Ya-Min
Song, Tian-Qiang
Zhang, Li
Xie, Yan
Zhou, Yong-He
Lu, Wei
author_sort Zhang, Shu-Wen
collection PubMed
description BACKGROUND: Treatments for patients with early‐stage hepatocellular carcinoma (HCC) include liver transplantation (LT), liver resection (LR), radiofrequency ablation (RFA), and microwave ablation (MWA), are critical for their long-term survival. However, a computational model predicting treatment-independent prognosis of patients with HCC, such as overall survival (OS) and recurrence-free survival (RFS), is yet to be developed, to our best knowledge. The goal of this study is to identify prognostic factors associated with OS and RFS in patients with HCC and develop nomograms to predict them, respectively. METHODS: We retrospectively retrieved 730 patients with HCC from three hospitals in China and followed them up for 3 and 5 years after invasive treatment. All enrolled patients were randomly divided into the training cohort and the validation cohort with a 7:3 ratio, respectively. Independent prognostic factors associated with OS and RFS were determined by the multivariate Cox regression analysis. Two nomogram prognostic models were built and evaluated by concordance index (C-index), calibration curves, area under the receiver operating characteristics (ROC) curve, time-dependent area under the ROC curve (AUC), the Kaplan–Meier survival curve, and decision curve analyses (DCAs), respectively. RESULTS: Prognostic factors for OS and RFS were identified, and nomograms were successfully built. Calibration discrimination was good for both the OS and RFS nomogram prediction models (C-index: 0.750 and 0.746, respectively). For both nomograms, the AUC demonstrated outstanding predictive performance; the DCA shows that the model has good decision ability; and the calibration curve demonstrated strong predictive power. The nomograms successfully discriminated high-risk and low-risk patients with HCC associated with OS and RFS. CONCLUSIONS: We developed nomogram survival prediction models to predict the prognosis of HCC after invasive treatment with acceptable accuracies in both training and independent testing cohorts. The models may have clinical values in guiding the selection of clinical treatment strategies.
format Online
Article
Text
id pubmed-9352894
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93528942022-08-06 A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma Zhang, Shu-Wen Zhang, Ning-Ning Zhu, Wen-Wen Liu, Tian Lv, Jia-Yu Jiang, Wen-Tao Zhang, Ya-Min Song, Tian-Qiang Zhang, Li Xie, Yan Zhou, Yong-He Lu, Wei Front Oncol Oncology BACKGROUND: Treatments for patients with early‐stage hepatocellular carcinoma (HCC) include liver transplantation (LT), liver resection (LR), radiofrequency ablation (RFA), and microwave ablation (MWA), are critical for their long-term survival. However, a computational model predicting treatment-independent prognosis of patients with HCC, such as overall survival (OS) and recurrence-free survival (RFS), is yet to be developed, to our best knowledge. The goal of this study is to identify prognostic factors associated with OS and RFS in patients with HCC and develop nomograms to predict them, respectively. METHODS: We retrospectively retrieved 730 patients with HCC from three hospitals in China and followed them up for 3 and 5 years after invasive treatment. All enrolled patients were randomly divided into the training cohort and the validation cohort with a 7:3 ratio, respectively. Independent prognostic factors associated with OS and RFS were determined by the multivariate Cox regression analysis. Two nomogram prognostic models were built and evaluated by concordance index (C-index), calibration curves, area under the receiver operating characteristics (ROC) curve, time-dependent area under the ROC curve (AUC), the Kaplan–Meier survival curve, and decision curve analyses (DCAs), respectively. RESULTS: Prognostic factors for OS and RFS were identified, and nomograms were successfully built. Calibration discrimination was good for both the OS and RFS nomogram prediction models (C-index: 0.750 and 0.746, respectively). For both nomograms, the AUC demonstrated outstanding predictive performance; the DCA shows that the model has good decision ability; and the calibration curve demonstrated strong predictive power. The nomograms successfully discriminated high-risk and low-risk patients with HCC associated with OS and RFS. CONCLUSIONS: We developed nomogram survival prediction models to predict the prognosis of HCC after invasive treatment with acceptable accuracies in both training and independent testing cohorts. The models may have clinical values in guiding the selection of clinical treatment strategies. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9352894/ /pubmed/35936698 http://dx.doi.org/10.3389/fonc.2022.946531 Text en Copyright © 2022 Zhang, Zhang, Zhu, Liu, Lv, Jiang, Zhang, Song, Zhang, Xie, Zhou and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Shu-Wen
Zhang, Ning-Ning
Zhu, Wen-Wen
Liu, Tian
Lv, Jia-Yu
Jiang, Wen-Tao
Zhang, Ya-Min
Song, Tian-Qiang
Zhang, Li
Xie, Yan
Zhou, Yong-He
Lu, Wei
A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
title A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
title_full A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
title_fullStr A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
title_full_unstemmed A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
title_short A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
title_sort novel nomogram model to predict the recurrence-free survival and overall survival of hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352894/
https://www.ncbi.nlm.nih.gov/pubmed/35936698
http://dx.doi.org/10.3389/fonc.2022.946531
work_keys_str_mv AT zhangshuwen anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhangningning anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhuwenwen anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT liutian anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT lvjiayu anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT jiangwentao anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhangyamin anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT songtianqiang anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhangli anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT xieyan anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhouyonghe anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT luwei anovelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhangshuwen novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhangningning novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhuwenwen novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT liutian novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT lvjiayu novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT jiangwentao novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhangyamin novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT songtianqiang novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhangli novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT xieyan novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT zhouyonghe novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma
AT luwei novelnomogrammodeltopredicttherecurrencefreesurvivalandoverallsurvivalofhepatocellularcarcinoma